Psyence Biomedical (PBM) Equity Average (2024 - 2025)
Psyence Biomedical (PBM) recorded quarterly Equity Average of $2.7 million in Q1 2025, up 144.71% quarter-over-quarter from -$6.1 million in Q3 2024.
Psyence Biomedical (PBM) Equity Average (2024 - 2025) Analysis & Trends
Psyence Biomedical's Equity Average history runs 2 years deep, the most recent figure standing at $2.7 million for Q1 2025.
- In Q1 2025, Equity Average changed N/A year-over-year to $2.7 million; the TTM figure through Mar 2025 stood at $2.7 million (changed N/A YoY), while the FY2025 annual figure was -$2.1 million, changed N/A from the prior year.
- Equity Average was $2.7 million for Q1 2025 at Psyence Biomedical, up from -$6.1 million in the prior quarter.
- In the past five years, Equity Average ranged from a high of $2.7 million in Q1 2025 to a low of -$6.1 million in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | 3.50 Bn |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | 783.14 Mn |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | 3.76 Mn |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | 1.01 Bn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | 21.35 Mn |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 19.01 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | 516.41 Mn |
| 10 | Regeneron Pharmaceuticals | 66.09 Bn | 57.33 Bn | 3.31 Bn | 31.34 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 2.73 Mn |
| Sep 30, 2024 | -6.11 Mn |